A phase i study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 5, 2011, Pages 1233-1241

  Simon, George R ^a,d   Ilaria Jr , Robert L ^b   Sovak, Mika A ^c,e   Williams, Charles C ^a   Haura, Eric B ^a   Cleverly, Ann L ^b   Sykes, Amanda K ^b   Wagner, Margaret M ^b   De Alwis, Dinesh P ^b   Slapak, Christopher A ^b   Miller, Mary A ^b   Spriggs, David R ^c  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e GENENTECH INC   (United States)

Author keywords

Chemotherapy; LY573636; Phase I; Solid tumors; Tasisulam

Indexed keywords

ALBUMIN; TASISULAM; WARFARIN;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; BLOOD TOXICITY; CANCER RESISTANCE; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMOPTYSIS; HUMAN; HYPOKALEMIA; LEAN BODY WEIGHT; LEUKOCYTE COUNT; LEUKOPENIA; LOADING DRUG DOSE; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PANCYTOPENIA; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROTHROMBIN TIME; SIDE EFFECT; SOLID TUMOR; SPINAL CORD COMPRESSION; STOMATITIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THYMOMA; TURNOVER TIME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTINEOPLASTIC AGENTS; BENZAMIDES; CHROMATOGRAPHY, LIQUID; FEMALE; HALF-LIFE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; REPRODUCIBILITY OF RESULTS; SULFONAMIDES; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 82455212082     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1593-0     Document Type: Article

References (14)

1. Corbett TH, Valeriote FA, Polin L et al (1992) Discovery of solid tumor active agents using a soft-agar-colony-formation disk-diffusion-assay. In: Valeriote FA, Corbett TH, Baker LH (eds) Cytotoxic anticancer drugs: models and concepts for drug discovery and development. Kluwer, Norwell, pp 35-87
2. KD Paull RH Shoemaker L Hodes A Monks DA Scudiero L Rubinstein J Plowman MR Boyd 1989 Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm J Natl Cancer Inst 81 1088 1092 2738938 10.1093/jnci/81.14.1088 1:STN:280:DyaL1M3ptlyrsw%3D%3D (Pubitemid 19175145)
3. T Haritunians S Gueller J O'Kelly R Ilaria Jr HP Koeffler 2008 Novel acyl sulfonamide LY573636-sodium: effect on hematopoietic malignant cells Oncol Rep 20 1237 1242 18949427 1:CAS:528:DC%2BD1cXhsVaqtr3N
4. MJ Ratain R Mick RL Schilsky M Siegler 1993 Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents J Natl Cancer Inst 85 1637 1643 8411243 10.1093/jnci/85.20. 1637 1:STN:280:DyaK2c%2Fhs1Klsw%3D%3D (Pubitemid 23315422)
5. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors, European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
6. BP Smith FR Vandenhende KA DeSante NA Farid PA Welch JT Callaghan ST Forgue 2000 Confidence interval criteria for assessment of dose proportionality Pharm Res 17 1278 1283 11145235 10.1023/A:1026451721686 1:CAS:528:DC%2BD3MXit1am
7. H Akaike 1974 A new look at the statistical model identification IEEE Trans Auton Control 19 716 723 10.1109/TAC.1974.1100705
8. Rowland M, Tozer TN (1995) Clinical pharmacokinetics: concepts and applications, 3rd edn. Lippincott Williams & Wilkins, Philadelphia, p 149
9. K Sterling 1951 The turnover rate of serum albumin in man as measured by I131-tagged albumin J Clin Invest 30 1228 1237 14888700 10.1172/JCI102542 1:CAS:528:DyaG38Xht1SjsA%3D%3D
10. S Janmahasatian SB Duffull S Ash LC Ward NM Byrne B Green 2005 Quantification of lean bodyweight Clin Pharmacokinet 44 1051 1065 16176118 10.2165/00003088-200544100-00004 (Pubitemid 41356391)
11. B Green SB Duffull 2004 What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 58 119 133 15255794 10.1111/j.1365-2125.2004.02157.x (Pubitemid 39043992)
12. Slapak CA, LoRusso PM, Mendelson D, Sykes AK, de Alwis DP, Wagner MM, Ilaria RL, Gordon MS (2007) Phase 1 study of LY573636-sodium, an acylsulfonamide anti-cancer compound with a novel mechanism of action, administered as 24-hour continuous infusion in patients with advanced solid tumors. J Clin Oncol 25:107s (suppl 18s; abstr 2542)
13. M Gordon S McMeekin S Temkin W Tew S Yapp G Scambia O Streltsova C Kaiser R Ilaria K Look 2009 A phase II, single-arm study of tasisulam sodium (LY573636 sodium) as 2nd-4th line therapy for platinum-resistant ovarian cancer. AACR NCI EORTC international conference: molecular targets and cancer therapeutics Mol Cancer Ther 8 12 suppl B197
14. Kirkwood JM, Gonzalez R, Reintgen DS, Clingan PR, McWilliams RR, Ilaria RL, de Alwis DP, Zimmermann A, Brown MP, Millward M (2010) A phase II study of tasisulam sodium (LY573636) as second-line treatment for patients with unresectable or metastatic melanoma. J Clin Oncol 28:7s (suppl; abstr 8541)